Ibrutinib contraindicated population: Notice for patients with severe liver dysfunction and active bleeding
Ibrutinib, although an important targeted drug for B-cell malignancies, is not suitable for everyone. Patients with severe hepatic impairment and active bleeding are clearly high-risk groups; before administration, a physician must conduct a strict evaluation, and if necessary, the drug should be contraindicated or the regimen adjusted to ensure treatment safety.
I. Information for Patients with Severe Hepatic Impairment
Clear contraindication boundary: Patients with severe hepatic impairment (Child-Pugh class C) should avoid Ibrutinib, because the drug is mainly metabolized by the liver; slowed clearance can lead to significantly elevated blood drug concentrations and increased toxicity risk.
Mild to moderate requires adjustment: Mild to moderate hepatic impairment is not an absolute contraindication, but the drug should be used at a reduced dose under physician guidance with enhanced monitoring.
Closely monitor indicators: During treatment, periodically recheck liver function (transaminases, bilirubin, etc.); seek medical attention promptly if jaundice, fatigue, or decreased appetite occurs.
Be alert to drug accumulation: Avoid concomitant use of other drugs metabolized by the liver or with hepatotoxicity to reduce liver burden.
II. Information for Patients with Active Bleeding
Contraindicated in active bleeding: Ibrutinib is contraindicated in patients with active bleeding (such as gastrointestinal bleeding, intracranial bleeding, etc.), because BTK inhibition can affect platelet function and worsen bleeding risk.
Use with caution in those with bleeding tendency: For patients with a history of bleeding disorders or those currently using anticoagulant or antiplatelet drugs, the physician must weigh the benefits and risks before deciding whether to use the drug.
Suspend before surgery: Before planned surgery or invasive procedures, Ibrutinib should be suspended for several days as directed by the physician to reduce intraoperative bleeding risk.
Watch for bleeding signals: During treatment, if large bruises, uncontrollable nosebleeds, black stool, hematuria, or headache and vomiting occur, seek medical attention immediately.
Disclaimer：《Ibrutinib contraindicated population: Notice for patients with severe liver dysfunction and active bleeding》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！